Patents by Inventor Thomas A. Leedom

Thomas A. Leedom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense oligonucleotides optimized for kidney targeting
    Patent number: 8258105
    Abstract: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF) in the kidney.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: September 4, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Andrew M. Siwkowski, Edward Wancewicz, Thomas A. Leedom, Lynnetta Watts, Mausumee Guha, Brett P. Monia
  • MODULATION OF SGLT-2 EXPRESSION
    Publication number: 20120196921
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.
    Type: Application
    Filed: November 18, 2011
    Publication date: August 2, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Edward Wancewicz, Brett P. Monia, Andrew M. Siwkowski, Lynnetta Watts, Thomas A. Leedom
  • MODULATION OF SGLT2 EXPRESSION
    Publication number: 20100324122
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.
    Type: Application
    Filed: June 24, 2008
    Publication date: December 23, 2010
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Edward Wancewicz, Brett P. Monia, Andrew M. Siwkowski, Lynnetta Watts, Thomas A. Leedom